Steris Plc. (STE) has recently witnessed a flurry of investment activity with notable names such as the
Czech National Bank, Morgan Stanley, UBS AM, Alliancebernstein, and BNP Paribas increasing stake or maintaining a positive outlook. STE has been
upgraded to a 'strong buy' by some analysts whilst others affirm a 'buy' rating with target prices reaching up to
$295. Following solid Q1 2026 results featuring
9% revenue growth and a 67% jump in
free cash flow, the company has also updated its financial outlook. These successive positive developments pushed STE to a
new 52-week high. Future prospects look favorable, with
increased dividends and plans to
bring pharmaceutical manufacturing back to the U.S. STE's growth is reflected in a
5-year shareholder CAGR of 8.5%. However, caution is advisable as some insiders have recently
sold US$5.1m of their shares. Furthermore,
CFO Michael J. Tokich is set to be succeeded by Karen L. Burton, potentially heralding an era of strategic change for STE.
Steris Plc STE News Analytics from Thu, 23 Jan 2025 08:00:00 GMT to Sun, 21 Sep 2025 00:50:02 GMT -
Rating 7
- Innovation 2
- Information 8
- Rumor -5
